BACKGROUND: Epigenetic studies demonstrate that an association may exist between methylation of the @entity1968 receptor beta2 (RARb2) gene promoter and @entity0 onset risk, @entity5 stage, and histological grade, however the results of these studies are not consistent. Hence, we performed this meta-analysis to ascertain a more comprehensive and accurate association. MATERIALS AND METHODS: Relevant studies were retrieved from the PubMed, Embase and Chinese National Knowledge Infrastructure databases up to February 28, 2015. After two independent reviewers screened the studies and extracted the necessary data, meta-analysis was performed using Review Manager 5.2 software. RESULTS: Nineteen eligible articles, including 20 studies, were included in our analysis. Compared to non-cancerous controls, the frequency of RARb2 methylation was 7.27 times higher in @entity1 with @entity0 (odds ratio (OR) = 7.27, 95% confidence interval (CI) = 3.01-17.52). Compared to late-stage RARb2 methylated @entity1 , the pooled OR of early-stage ones was 0.81 (OR = 0.81, 95% CI = 0.55-1.17). The OR of low-grade RARb2 methylated @entity1 was 0.96 (OR = 0.96, 95% CI = 0.74-1.25) compared to high-grade RARb2 methylated @entity1 . CONCLUSION: RARb2 methylation is significantly increased in @entity0 samples when compared to non-cancerous controls. RARb2 could serve as a potential epigenetic marker for @entity0 detection and management.

Promoter Methylation of the @entity1968 Receptor Beta2 (RARb2) Is Associated with Increased Risk of XXXX : A PRISMA Compliant Meta-Analysis.

@entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1968 :: ('MESH:D014212', 'Chemical') :: ['retinoic acid']
@entity0 :: (MESH:D001943,Disease) :: ['Breast Cancer']
